EWA
IMDX

EverSource Wealth Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

EverSource Wealth Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5K Hold
5,000
– – ﹤0.01% 2157
2026
Q1 		$16.4K Hold
5,000
– – ﹤0.01% 2629
2025
Q4 		$37.5K Hold
5,000
– – ﹤0.01% 1952
2025
Q3 		$16.6K Hold
5,000
– – ﹤0.01% 2493
2025
Q2 		$15.1K Buy
+5,000
New +$15.1K ﹤0.01% 2515

Other funds holding IMDX

FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
PSB
Piscataqua Savings Bank Portsmouth, New Hampshire $148M AUM 32.61% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

EverSource Wealth Advisors's IMDX Position: Q2 2026 in Review

EverSource Wealth Advisors held its Insight Molecular Diagnostics (IMDX) position steady in Q2 2026 at 5,000 shares worth $29.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2157.

EverSource Wealth Advisors first reported a position in IMDX in Q2 2025 and has held it in 5 quarters since. The position peaked at $37.5K in Q4 2025. 6 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • EverSource Wealth Advisors held 5,000 shares of Insight Molecular Diagnostics worth $29.5K as of Q2 2026.
  • EverSource Wealth Advisors left its Insight Molecular Diagnostics share count unchanged in Q2 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2157 holding.
  • EverSource Wealth Advisors first reported a position in Insight Molecular Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • EverSource Wealth Advisors's Insight Molecular Diagnostics position peaked at $37.5K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.